Repligen Corporation (RGEN)
- Previous Close
171.28 - Open
169.82 - Bid 167.57 x 100
- Ask 167.95 x 100
- Day's Range
165.93 - 173.41 - 52 Week Range
110.45 - 211.13 - Volume
273,339 - Avg. Volume
523,048 - Market Cap (intraday)
9.369B - Beta (5Y Monthly) 1.01
- PE Ratio (TTM)
226.73 - EPS (TTM)
0.74 - Earnings Date May 1, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
204.62
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
www.repligen.com1,783
Full Time Employees
December 31
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: RGEN
Performance Overview: RGEN
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RGEN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RGEN
Valuation Measures
Market Cap
9.56B
Enterprise Value
9.52B
Trailing P/E
231.46
Forward P/E
119.05
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
15.12
Price/Book (mrq)
4.85
Enterprise Value/Revenue
14.91
Enterprise Value/EBITDA
70.99
Financial Highlights
Profitability and Income Statement
Profit Margin
6.51%
Return on Assets (ttm)
1.31%
Return on Equity (ttm)
2.14%
Revenue (ttm)
638.76M
Net Income Avi to Common (ttm)
41.58M
Diluted EPS (ttm)
0.74
Balance Sheet and Cash Flow
Total Cash (mrq)
751.32M
Total Debt/Equity (mrq)
36.11%
Levered Free Cash Flow (ttm)
71.08M
Research Analysis: RGEN
Company Insights: RGEN
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: RGEN
RGEN: Lowering target price to $172.00
REPLIGEN CORP has an Investment Rating of HOLD; a target price of $172.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Low.
RatingPrice TargetRGEN: Raising target price to $191.00
REPLIGEN CORP has an Investment Rating of HOLD; a target price of $191.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Low.
RatingPrice TargetRGEN: Lowering target price to $187.00
REPLIGEN CORP has an Investment Rating of HOLD; a target price of $187.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetRGEN: Lowering target price to $193.00
REPLIGEN CORP has an Investment Rating of HOLD; a target price of $193.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice Target